Epineuron Technologies Closes Financing for Breakthrough Neuroregenerative Solution

May 26, 2020

Congratulations to The Forge alumnus Epineuron Technologies Inc., that announced the completion of a financing round led by leading medical technology investors, including the Ontario Centers for Excellence (OCE) and the Ontario Brain Institute (OBI). The financing will support growing Epineuron’s team and continue with product development and clinical validation. Epineuron is a bioelectronic medicine company bringing a new standard of care for peripheral nerve repair and regeneration.

In 2018, it became one of the first Canadian companies to have a lead product be designated as a Breakthrough Device by the US Food and Drug Administration (FDA) for the company’s temporary peripheral nerve stimulation (TPNS) system. “This is a pivotal moment in the company’s trajectory to realizing its vision of providing patients with a therapeutic option after nerve surgery for the very first time, leading to enhanced functional outcomes and ushering in a new era in nerve repair,” said Mike Willand, PhD, CTO of Epineuron.

Epineuron is developing a suite of surgical solutions for repairing and treating peripheral nerve injuries with the mission of becoming the world leader in bioelectronic nerve care, starting with its neuroregenerative therapy. Epineuron’s lead product will be the world’s first commercial bioelectronic medicine used to accelerate regeneration of injured nerves.

To learn more visit:

·       Epineuron Technologies Inc.
·       Ontario Brain Institute: Epineuron Technologies Closes Financing for its Breakthrough Nerve Regeneration Device (May 26, 2020)